Kutsch N, Holmes EE, Robrecht S, Schuler G, et al. Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients. Leuk Lymphoma 2023;64:478-482.
PMID: 36423347